{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:22:41Z","timestamp":1761646961196,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Biology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.repbio.2019.03.005","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T02:02:38Z","timestamp":1558749758000},"page":"145-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol"],"prefix":"10.1016","volume":"19","author":[{"given":"Sherif","family":"Gaafar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalal","family":"El-Gezary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan A.","family":"El Maghraby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repbio.2019.03.005_bib0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","article-title":"Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review","volume":"8","author":"Delvingne","year":"2002","journal-title":"Hum Reprod Update"},{"year":"2007","series-title":"Saving mothers\u2019 lives: reviewing maternal deaths to make motherhood safer 2003\u20132005 VIIth Report","author":"Confidential Enquiry into Maternal and Child Health","key":"10.1016\/j.repbio.2019.03.005_bib0010"},{"key":"10.1016\/j.repbio.2019.03.005_bib0015","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/humrep\/deq080","article-title":"Maternal death related to IVF in the Netherlands 1984\u20132008","volume":"25","author":"Braat","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.repbio.2019.03.005_bib0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/molehr\/8.5.409","article-title":"The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome","volume":"8","author":"Albert","year":"2002","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.repbio.2019.03.005_bib0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1537-1891(03)00011-9","article-title":"Regulation of vascular permeability by vascular endothelial growth factors","volume":"39","author":"Bates","year":"2002","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.repbio.2019.03.005_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(94)93001-5","article-title":"Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome","volume":"344","author":"McClure","year":"1994","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.repbio.2019.03.005_bib0035","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1210\/jc.2011-0075","article-title":"Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment","volume":"96","author":"G\u00f3mez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.repbio.2019.03.005_bib0040","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade","volume":"143","author":"G\u00f3mez","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.repbio.2019.03.005_bib0045","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/87895","article-title":"The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor","volume":"7","author":"Basu","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.repbio.2019.03.005_bib0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/oxfordjournals.humrep.a137613","article-title":"Dopamine treatment for severe ovarian hyperstimulation syndrome","volume":"7","author":"Ferraretti","year":"1992","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.repbio.2019.03.005_bib0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/14647273.2013.833348","article-title":"Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis","volume":"16","author":"Baumgarten","year":"2013","journal-title":"Hum Fertil"},{"key":"10.1016\/j.repbio.2019.03.005_bib0060","first-page":"157","article-title":"Expression of vascular permeability factor\/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development","volume":"146","author":"Kamat","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.repbio.2019.03.005_bib0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.repbio.2019.03.005_bib0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0015-0282(16)55188-7","article-title":"Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment","volume":"58","author":"Navot","year":"1992","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.repbio.2019.03.005_bib0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mjafi.2017.04.006","article-title":"Severe ovarian hyperstimulation syndrome: can we eliminate it through a multipronged approach?","volume":"74","author":"Naredi","year":"2018","journal-title":"Med J Armed Forces India"},{"issue":"1","key":"10.1016\/j.repbio.2019.03.005_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.repbio.2017.01.004","article-title":"Gonadotropin-releasing hormone agonist (GnRHa) trigger \u2013 state of the art","volume":"17","author":"Dosouto","year":"2017","journal-title":"Reprod Biol"},{"key":"10.1016\/j.repbio.2019.03.005_bib0085","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.fertnstert.2013.05.028","article-title":"Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone\u2013gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"100","author":"Fatemi","year":"2013","journal-title":"Fertil Steril"},{"issue":"10","key":"10.1016\/j.repbio.2019.03.005_bib0090","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-free clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.repbio.2019.03.005_bib0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1472-6483(10)60006-5","article-title":"Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study","volume":"8","author":"Humaidan","year":"2009","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"10.1016\/j.repbio.2019.03.005_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rbmo.2017.09.014","article-title":"GnRHa trigger and luteal coasting \u2013 a new approach for the OHSS high-risk patient?","volume":"36","author":"Lawrenz","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.repbio.2019.03.005_bib0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/humupd\/dmn008","article-title":"Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome","volume":"14","author":"Soares","year":"2008","journal-title":"Hum Reprod Update"},{"issue":"8","key":"10.1016\/j.repbio.2019.03.005_bib0110","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3109\/09513590.2013.801440","article-title":"The effect of cabergoline on folicular microenvironment profile in patients with high risk of OHSS","volume":"29","author":"Guvendag Guven","year":"2013","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"10.1016\/j.repbio.2019.03.005_bib0115","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00404-013-2875-z","article-title":"Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting","volume":"288","author":"Esinler","year":"2013","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.repbio.2019.03.005_bib0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","article-title":"Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial","volume":"29","author":"Tehraninejad","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.repbio.2019.03.005_bib0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejogrb.2017.03.016","article-title":"Combining several interventions to reduce the incidence of OHSS: a prospective cohort study","volume":"212","author":"Elmahdy","year":"2017","journal-title":"Ur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.repbio.2019.03.005_bib0130","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model","volume":"147","author":"Gomez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.repbio.2019.03.005_bib0135","first-page":"008605","article-title":"Cabergoline for preventing ovarian hyperstimulation syndrome","volume":"2","author":"Tang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.repbio.2019.03.005_bib0140","first-page":"CD008605","article-title":"2016 Dopamine agonists for preventing ovarian hyperstimulation syndrome","volume":"11","author":"Tang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.repbio.2019.03.005_bib0145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejogrb.2012.08.008","article-title":"Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study","volume":"165","author":"Shaltout","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.repbio.2019.03.005_bib0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1472-6483(10)62518-7","article-title":"Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome","volume":"20","author":"Ahmadi","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.repbio.2019.03.005_bib0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fertnstert.2011.07.325","article-title":"Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study","volume":"96","author":"Amir","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.repbio.2019.03.005_bib0160","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carizza","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.repbio.2019.03.005_bib0165","first-page":"61","article-title":"Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone","volume":"24","author":"Edeen","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.repbio.2019.03.005_bib0170","first-page":"35","article-title":"Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients","volume":"3","author":"Sohrabvand","year":"2009","journal-title":"Int J Fertil Steril"},{"key":"10.1016\/j.repbio.2019.03.005_bib0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","article-title":"Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial","volume":"29","author":"Tehraninejad","year":"2012","journal-title":"J Assist Reprod Genet"},{"issue":"6","key":"10.1016\/j.repbio.2019.03.005_bib0180","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.rbmo.2013.03.002","article-title":"Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial","volume":"26","author":"Seow","year":"2013","journal-title":"Reprod Biomed Online"}],"container-title":["Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1642431X19300324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1642431X19300324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:17:53Z","timestamp":1761646673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1642431X19300324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1642431X19300324"],"URL":"https:\/\/doi.org\/10.1016\/j.repbio.2019.03.005","relation":{},"ISSN":["1642-431X"],"issn-type":[{"type":"print","value":"1642-431X"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol","name":"articletitle","label":"Article Title"},{"value":"Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repbio.2019.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of Society for Biology of Reproduction & the Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn.","name":"copyright","label":"Copyright"}]}}